Source library for Good AI Practice.
verified anchorsFDA guiding principles for Good AI Practice in drug development
2026-01-14 · FDA page for common Good AI Practice principles in drug development.
EMA and FDA common AI principles news
2026-01-14 · EU-facing publication context for the common principles.
EMA/HMA AI in medicinal product lifecycle
2024-09-30 · Broader medicinal-product lifecycle reflection layer for AI use and governance.
FDA/Health Canada/MHRA GMLP principles
2021-10-27 · Ten guiding principles for Good Machine Learning Practice for medical device development.
What can be used publicly and what must stay bounded.
public-safeOfficial source first
Use regulator, source-owner, EUR-Lex, FDA, EMA, ICH, ISO/IEC, ISPE, IMDRF, Health Canada, MHRA or similar authority/source-owner pages before commentary.
Paid-source boundary
Where a standard or guide is protected, the page names the source and describes public-safe implications without reproducing protected clause text.
Status visible
Every source needs date/status language so draft, final, watch item, and effective/applicable dates are not mixed.
Interpretation separated
Source fact and iFeed interpretation must remain visibly separated before any checklist is published.
Objects that deserve stable child pages.
future expansionFDA/EMA Good AI Practice principles
Common principles for AI in drug development released in January 2026.
EMA/HMA AI lifecycle reflection
Medicinal-product lifecycle context for AI use and risk management.
FDA AI drug development page
US source hub for AI in drug-development activity.
GMLP medical-device principles
Comparator source for device ML development; separate from medicines AI.
Context-of-use principle
The same model can carry different risk depending on decision context.
Lifecycle management principle
Model performance, change, and monitoring remain active after deployment.